{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:57Z","timestamp":1788778857119,"version":"build-2803163510"},"reference-count":135,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101144","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:17:56Z","timestamp":1578741476000},"page":"101144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Second malignancies in multiple myeloma; emerging patterns and future directions"],"prefix":"10.1016","volume":"33","author":[{"given":"Kylee","family":"Maclachlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.beha.2020.101144_bib1","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2020.101144_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00277-018-3316-7","article-title":"Evaluation of revised international staging system (R-ISS) for transplant-eligible multiple myeloma patients","volume":"97","author":"Gonzalez-Calle","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/17474086.2014.864230","article-title":"Initial treatment of transplant-ineligible patients in multiple myeloma","volume":"7","author":"Mateos","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101144_bib7","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2019-125842","article-title":"Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: a clinical and correlative phase 2 study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101144_bib8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.beha.2020.101144_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2020.101144_bib10","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101144_bib13","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/bcj.2013.19","article-title":"Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics","volume":"3","author":"Razavi","year":"2013","journal-title":"Blood Canc J"},{"issue":"15","key":"10.1016\/j.beha.2020.101144_bib14","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101144_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958\u20131996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Canc"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib17","first-page":"4507","article-title":"Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study","volume":"32","author":"Chakraborty","year":"2012","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068041","article-title":"Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study","volume":"8","author":"Tzeng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2020.101144_bib19","doi-asserted-by":"crossref","first-page":"22084","DOI":"10.1038\/srep22084","article-title":"Risk of second primary cancers in multiple myeloma survivors in German and Swedish cancer registries","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New cancers after autotransplantations for multiple myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib21","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bjh.15426","article-title":"Second primary malignancy after multiple myeloma-population trends and cause-specific mortality","volume":"182","author":"Costa","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/cncr.31853","article-title":"Outcomes of secondary solid tumor malignancies among patients with myeloma: a population-based study","volume":"125","author":"Barth","year":"2019","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.beha.2020.101144_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic Myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2020.101144_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","article-title":"Incidence and survival of therapy related myeloid neoplasm in United States","volume":"71","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib29","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2020.101144_bib30","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"\u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2020.101144_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13050","article-title":"Increasing therapy-related myeloid neoplasms in multiple myeloma","volume":"49","author":"Fern\u00e1ndez-Caballero","year":"2019","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib34","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias","volume":"90","author":"Fianchi","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2020.101144_bib35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"issue":"7540","key":"10.1016\/j.beha.2020.101144_bib36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.beha.2020.101144_bib37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101144_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.beha.2019.02.003","article-title":"Therapy-related myeloid neoplasms after treatment for plasma-cell disorders","volume":"32","author":"Chung","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2013.191","article-title":"Application of the International Prognostic Scoring System-Revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia","volume":"28","author":"Ok","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101144_bib42","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1200\/JCO.2017.35.15_suppl.8043","article-title":"Outcomes of secondary cancers among myeloma survivors","volume":"35","author":"Castillo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101144_bib43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12\u2009482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib44","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Canc J"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101144_bib46","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1038\/bcj.2014.63","article-title":"Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups","volume":"4","author":"Ailawadhi","year":"2014","journal-title":"Blood Canc J"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib47","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1038\/ncomms12050","article-title":"Genome-wide association study identifies multiple susceptibility loci for multiple myeloma","volume":"7","author":"Mitchell","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/leu.2013.344","article-title":"Inherited genetic susceptibility to multiple myeloma","volume":"28","author":"Morgan","year":"2014","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.beha.2020.101144_bib50","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/hmg\/ddm273","article-title":"Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma","volume":"16","author":"Hayden","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.blre.2016.11.002","article-title":"Therapy-related myelodysplastic syndromes, or are they?","volume":"31","author":"Abou Zahr","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djj001","article-title":"Cancer survivorship\u2014genetic susceptibility and second primary cancers: research strategies and recommendations","volume":"98","author":"Travis","year":"2006","journal-title":"JNCI: J. Natl. Canc.Instit."},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101144_bib53","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/jco.2015.33.15_suppl.1510","article-title":"Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101144_bib54","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fgene.2019.00424","article-title":"Germline risk contribution to genomic instability in multiple myeloma","volume":"10","author":"Janz","year":"2019","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","article-title":"Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","volume":"49","author":"Schulz","year":"2012","journal-title":"J Med Genet"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/leu.2011.262","article-title":"Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma","volume":"26","author":"Landgren","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/1055-9965.EPI-14-1145","article-title":"A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium","volume":"24","author":"Andreotti","year":"2015","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib59","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/ijc.27898","article-title":"Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies","volume":"132","author":"Psaltopoulou","year":"2013","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CEJ.0000000000000001","article-title":"Alcohol drinking and multiple myeloma risk--a systematic review and meta-analysis of the dose-risk relationship","volume":"23","author":"Rota","year":"2014","journal-title":"Eur J Cancer Prev"},{"issue":"9","key":"10.1016\/j.beha.2020.101144_bib61","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1055-9965.EPI-13-0334","article-title":"A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium","volume":"22","author":"Andreotti","year":"2013","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2016","journal-title":"JNCI: J. Natl. Canc.Instit."},{"issue":"24","key":"10.1016\/j.beha.2020.101144_bib64","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2020.101144_bib65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2018.03.007","article-title":"Myeloid derived-suppressor cells: their role in cancer and obesity","volume":"51","author":"Ostrand-Rosenberg","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers10040104","article-title":"The critical role of inflammation in the pathogenesis and progression of myeloid malignancies","volume":"10","author":"Craver","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101144_bib67","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1200\/jco.2014.32.15_suppl.7055","article-title":"Association of obesity with cytogenetic risk in adult acute myeloid leukemia (AML)","volume":"32","author":"Finn","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.beha.2020.101144_bib68","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/bloodadvances.2017007930","article-title":"The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study","volume":"1","author":"Jonsdottir","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10428194.2010.529207","article-title":"Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma","volume":"52","author":"Hasskarl","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.beha.2020.101144_bib70","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent orange exposure and monoclonal gammopathy of undetermined significance: an operation Ranch hand Veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol."},{"issue":"25","key":"10.1016\/j.beha.2020.101144_bib71","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib72","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/10428194.2017.1361026","article-title":"Host-related immunodeficiency in the development of multiple myeloma","volume":"59","author":"Dosani","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib73","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/ijc.21745","article-title":"Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study","volume":"118","author":"Landgren","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-5-59","article-title":"Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma","volume":"5","author":"Hemminki","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-016-2859-8","article-title":"History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study","volume":"96","author":"Lindqvist","year":"2017","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.beha.2020.101144_bib76","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.beha.2020.101144_bib78","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V120.21.1805.1805","article-title":"Early myelodysplastic changes present in substantial proportion of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients","volume":"120","author":"Korde","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib79","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3324\/haematol.2012.064121","article-title":"Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?","volume":"97","author":"Matarraz","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101144_bib80","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/leu.2014.103","article-title":"Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations","volume":"28","author":"Matarraz","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib81","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib82","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beha.2019.02.006","article-title":"Clonal Hematopoiesis and therapy related MDS\/AML","volume":"32","author":"Desai","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2020.101144_bib84","first-page":"848739","article-title":"Oncologic therapy shapes the fitness landscape of clonal hematopoiesis","author":"Bolton","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.beha.2020.101144_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","author":"Landgren","year":"2019","journal-title":"JAMA Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101144_bib86","first-page":"4333","article-title":"Immune microenvironment contributes to dysregulation of Aid\/Apobec expression and genomic instability in multiple myeloma","volume":"130","author":"Talluri","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2020.101144_bib88","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib89","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br J Canc"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib90","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib91","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1038\/ncomms12605","article-title":"Mutational signatures of ionizing radiation in second malignancies","volume":"7","author":"Behjati","year":"2016","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101144_bib92","first-page":"332","article-title":"Effect of autologous hematopoietic stem cell transplant (aHSCT) on the development of second primary malignancies (SPM) in multiple myeloma patients","volume":"130","author":"Rosenberg","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2007-06-097444","article-title":"Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989","volume":"111","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101144_bib94","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib95","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.clml.2019.09.008","article-title":"Timing the initiation of multiple myeloma","volume":"19","author":"Maura","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2020.101144_bib96","article-title":"Timing the initiation of multiple myeloma","author":"Rustad","year":"2019","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.beha.2020.101144_bib97","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1200\/JCO.18.01006","article-title":"Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma","volume":"37","author":"Ahmedzai","year":"2019","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2020.101144_bib98","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2020.101144_bib99","first-page":"559","article-title":"Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time","volume":"17","author":"Kazandjian","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"19","key":"10.1016\/j.beha.2020.101144_bib100","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2020.101144_bib101","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.beha.2020.101144_bib102","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.beha.2020.101144_bib103","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol : Off. J. Am. Soc. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.beha.2020.101144_bib104","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2020.101144_bib106","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","article-title":"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance","volume":"120","author":"Usmani","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ejh.12903","article-title":"Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis","volume":"99","author":"Moreau","year":"2017","journal-title":"Eur J Haematol"},{"issue":"10068","key":"10.1016\/j.beha.2020.101144_bib108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2020.101144_bib109","doi-asserted-by":"crossref","unstructured":"Brioli A, Pezzi, A., Derudas, D., Petti, M.C., Zannetti, B.A., Ferrara, F., Rocchi, S., Nobile, F., Baraldi, A.M., Musto, P., Lanza, F., Mancuso, K., Canepa, L., Catalano, L., Lazzaro, A.D., Pinotti, G., Boccadoro, M., & Cavo, M. , editor Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and high-dose melphalan (HDM) as first line treatment for multiple myeloma (MM) is associated with a lower rate of second primary malignancies (SPMs) compared to TD Plus HDM2014.","DOI":"10.1182\/blood.V124.21.1182.1182"},{"issue":"3","key":"10.1016\/j.beha.2020.101144_bib110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/leu.2017.256","article-title":"Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation","volume":"32","author":"Chakraborty","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2020.101144_bib111","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41409-018-0177-6","article-title":"Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma","volume":"53","author":"Huang","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2020.101144_bib112","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101144_bib113","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101144_bib114","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2018-99-114311","article-title":"Bone marrow-based and longitudinal blood-based MRD tracking in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd): a correlative and clinical phase II study","volume":"132","author":"Landgren","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2020.101144_bib115","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101144_bib116","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib117","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr Jens","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib118","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101144_bib119","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2019-126392","article-title":"Revealing the impact of recurrent and rare structural variations in multiple myeloma","volume":"134","author":"Rustad","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101144_bib120","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib121","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.beha.2020.101144_bib122","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1309\/AJCPOP7APGDT9JIU","article-title":"Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon?: a clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens","volume":"138","author":"Reddi","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.beha.2020.101144_bib123","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib124","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2015.361","article-title":"Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors","volume":"30","author":"Mitra","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-Seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Canc J"},{"issue":"6","key":"10.1016\/j.beha.2020.101144_bib126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Canc J"},{"issue":"22","key":"10.1016\/j.beha.2020.101144_bib127","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101144_bib128","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2018-99-109709","article-title":"Identifying ultra-high risk smoldering multiple myeloma","volume":"132","author":"Akhlaghi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101144_bib129","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"19","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101144_bib130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2020.101144_bib131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2020.101144_bib132","first-page":"400","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial","volume":"130","author":"Goldschmidt","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101144_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.beha.2020.101144_bib134","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","article-title":"Targeting natural killer cells in solid tumors","volume":"16","author":"Habif","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.beha.2020.101144_bib135","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3389\/fimmu.2019.01703","article-title":"Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer","volume":"10","author":"Moon","year":"2019","journal-title":"Front Immunol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:38Z","timestamp":1761498338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300050"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101144","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second malignancies in multiple myeloma; emerging patterns and future directions","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101144"}}